Skip to main content Help with accessibility Skip to main navigation

Upadacitinib

Indication

Upadacitinib for previously treated moderately to severely active Crohn’s disease

NICE TA 905 - Upadacitinib for previously treated moderately to severely active Crohn’s disease

Red

Brand:

Nice TA:

905

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Gastro-intestinal system

Background

1.1 Upadacitinib is recommended as an option for treating moderately to severely active Crohn's disease in adults, only if:

• the disease has not responded well enough or lost response to a previous biological treatment or

• a previous biological treatment was not tolerated or

• tumour necrosis factor (TNF)-alpha inhibitors are contraindicated.

Upadacitinib is only recommended if the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 20 - Jul - 2023